Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients

Clinical and Vaccine Immunology

Volumn 21, Issue 6, 2014, Pages 867-876

  Van Der Velden, Maikel V W ^a   Geisberger, Alexander ^a   Dvorak, Thomas ^a   Portsmouth, Daniel ^a   Fritz, Richard ^a   Crowe, Brian A ^a   Herr, Wolfgang ^b   Distler, Eva ^b   Wagner, Eva M ^b   Zeitlinger, Markus ^c   Sauermann, Robert ^c   Stephan, Christoph ^d   Ehrlich, Hartmut J ^a   Barrett, P Noel ^a   Aichinger, Gerald ^a  

^a BAXTER BIOSCIENCE   (Austria)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; CHRONIC PATIENT; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; FEVER; HEADACHE; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT INDICATION; VERO CELL LINE; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANIMAL; ANTIBODY PRODUCTION; BLOOD; CELL LINE; CHLOROCEBUS AETHIOPS; CHRONIC DISEASE; CLINICAL TRIAL; CROSS REACTION; HEMAGGLUTINATION INHIBITION TEST; IMMUNIZATION; IMMUNOCOMPROMIZED PATIENT; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA A VIRUS (H5N1); INFLUENZA B VIRUS; INFLUENZA, HUMAN; LYMPHOCYTE ACTIVATION; MIDDLE AGED; T LYMPHOCYTE; VACCINATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CELL LINE; CERCOPITHECUS AETHIOPS; CHRONIC DISEASE; CROSS REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; T-LYMPHOCYTES; VACCINATION; VERO CELLS;

EID: 84901600545     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00065-14     Document Type: Article

References (41)

1. WHO. 2013. Areas with confirmed human cases for avian influenza A(H5N1) reported to WHO,2003-2013. World Health Organization, Geneva, Switzerland. http://gamapserver.who.int/mapLibrary/Files/Maps/2003-AvianInfluenza-GlobalMap- 01Feb13.png.
2. WHO. 2014. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. World Health Organization, Geneva, Switzerland. http://www.who.int/influenza/human-animal-interface/H5N1-cumulative-table- archives/en/index.html.
3. Center for Infectious Disease Research and Policy (CIDRAP). 2014. Ten new H7N9 cases push outbreak total past 300. Center for Infectious Disease Research and Policy, University of Minnesota, Minneapolis, MN. http://www.cidrap.umn. edu/news-perspective/2014/02/ten-new-h7n9-cases-push-outbreak-total-past-300.
4. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. 2006. Strategies for mitigating an influenza pandemic. Nature 442:448-452. http://dx.doi.org/10.1038/nature04795. (Pubitemid 44264793)
5. Ehrlich HJ, Müller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pöllabauer EM, Kistner O, Barrett PN, Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. 2008. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358:2573-2584. http://dx.doi.org/10.1056/NEJMoa073121.
6. Ehrlich HJ, Müller M, Fritsch S, Zeitlinger M, Berezuk G, Löw-Baselli A, van der Velden MV, Pollabauer EM, Maritsch F, Pavlova BG, Tambyah PA, Oh HM, Montomoli E, Kistner O, Noel Barrett P. 2009. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J. Infect. Dis. 200:1113-1118. http://dx.doi.org/10.1086/605608.
7. Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster JM, Leroux-Roels G. 2007. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370:580-589. http://dx.doi.org/10.1016/ S0140-6736(07)61297-5. (Pubitemid 47247854)
8. Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I. 2008. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J. Infect. Dis. 198:642-649. http://dx.doi.org/10.1086/590913.
9. Wu J, Fang HH, Chen JT, Zhou JC, Feng ZJ, Li CG, Qiu YZ, Liu Y, Lu M, Liu LY, Dong SS, Gao Q, Zhang XM, Wang N, Yin WD, Dong XP. 2009. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, dou-ble- blind, randomized trial. Clin. Infect. Dis. 48:1087-1095. http://dx.doi.org/10.1086/597401.
10. Díez-Domingo J, Garcés-Sanchez M, Baldó JM, Planelles MV, Ubeda I, JuBert A, Mares J, Moris P, Garcia-Corbeira P, Dramé M, Gillard P. 2010. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatr. Infect. Dis. J. 29:e35-e46. http://dx.doi.org/10.1097/INF. 0b013e3181daf921.
11. Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, Banzhoff A, Clemens R. 2010. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 126:e762-e770. http://dx.doi.org/10.1542/peds.2009-2628.
12. van der Velden MV, Fritz R, Pöllabauer EM, Portsmouth D, Howard MK, Kreil TR, Dvorak T, Fritsch S, Vesikari T, Diez-Domingo J, Richmond P, Lee BW, Kistner O, Ehrlich HJ, Barrett PN, Aichinger G. 2014. Safety and immunogenicity of a Vero cell culture-derived wholevirus influenza A(H5N1) vaccine in a pediatric population. J. Infect. Dis. 209:12-23. http://dx.doi.org/10.1093/ infdis/jit498.
13. European Centre for Disease Prevention and Control. 2008. Guidance: priority risk groups for influenza vaccination. European Centre for Disease Prevention and Control, Stockholm, Sweden. http://ecdc.europa.eu/en/ publications/Publications/0808-GUI-Priority-Risk-Groups-for-Influenza- Vaccination.pdf.
14. CDC. 2013. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2013-14. Centers for Disease Control and Prevention, Atlanta,GA. http://www.cdc.gov/flu/professionals/acip/specificpopulations.htm.
15. CDC. 2012. Chronic disease prevention and health promotion. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/chronicdisease/ overview/index.htm.
16. Lee N, Chan PK, Hui DS, Rainer TH, Wong E, Choi KW, Lui GC, Wong BC, Wong RY, Lam WY, Chu IM, Lai RW, Cockram CS, Sung JJ. 2009. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J. Infect. Dis. 200:492-500. http://dx.doi.org/10.1086/600383.
17. Meijer A, Jonges M, Abbink F, Ang W, van Beek J, Beersma M, Bloembergen P, Boucher C, Claas E, Donker G, van Gageldonk-Lafeber R, Isken L, de Jong A, Kroes A, Leenders S, van der Lubben M, Mascini E, Niesters B, Oosterheert JJ, Osterhaus A, Riesmeijer R, Riezebos-Brilman A, Schutten M, Sebens F, Stelma F, Swaan C, Timen A, van 't Veen A, van der Vries E, te Wierik M, Koopmans M. 2011. Oseltamivirresistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010. Antiviral Res. 92:81-89. http://dx.doi.org/10.1016/j.antiviral.2011.07.004.
18. Beck CR, McKenzie BC, Hashim AB, Harris RC, Zanuzdana A, Agboado G, Orton E, Béchard-Evans L, Morgan G, Stevenson C, Weston R, Mukaigawara M, Enstone J, Augustine G, Butt M, Kim S, Puleston R, Dabke G, Howard R, O'Boyle J, O'Brien M, Ahyow L, Denness H, Farmer S, Figureroa J, Fisher P, Greaves F, Haroon M, Haroon S, Hird C, Isba R, Ishola DA, Kerac M, Parish V, Roberts J, Rosser J, Theaker S, Wallace D, Wigglesworth N, Lingard L, Vinogradova Y, Horiuchi H, Peñalver J, Nguyen-Van-Tam JS. 2011. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. PLoS One 6:e29249. http://dx.doi.org/10.1371/journal. pone.0029249.
19. Kunisaki KM, Janoff EN. 2009. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect. Dis. 9:493-504. http://dx.doi.org/10.1016/S1473-3099(09)70175-6.
20. Kistner O, Howard MK, Spruth M, Wodal W, Brühl P, Gerencer M, Crowe BA, Savidis-Dacho H, Livey I, Reiter M, Mayerhofer I, Tauer C, Grillberger L, Mundt W, Falkner FG, Barrett PN. 2007. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25:6028-6036. http://dx.doi.org/10.1016/j.vaccine.2007.05. 013. (Pubitemid 47077543)
21. FDA. 2011. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/ BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/ Vaccines/ucm091977.pdf.
22. Committee for Proprietary Medicinal Products (CPMP). 1997. Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/BWP/214/96:18. The European Agency for the Evaluation of Medicinal Products, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003945.pdf.
23. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. (Lond.) 27:493-497.
24. Howard MK, Sabarth N, Savidis-Dacho H, Portsmouth D, Kistner O, Kreil TR, Ehrlich HJ, Barrett PN. 2011. H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model. PLoS One 6:e23791. http://dx.doi.org/10.1371/journal.pone.0023791.
25. European Medicines Agency. 2012. EPAR summary for the public: Vepacel: influenza vaccine (whole virion, inactivated). European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR---Summary-for-the-public/human/002089/WC500124226.pdf.
26. European Medicines Agency. 2012. EPAR summary for the public: pandemic influenza vaccine H5N1 Baxter AG. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Summary- for-the-public/human/001200/WC500049617.pdf.
27. Distler E, Schnürer E, Wagner E, von Auer C, Plachter B, Wehler D, Huber C, Kolbe K, Meyer RG, Herr W. 2008. Recovery of varicellazoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation. Biol. Blood Marrow Transplant 14:1417-1424. http://dx.doi.org/10.1016/j.bbmt.2008.09.004.
28. Bland JM, Altman DG. 1995. Calculating correlation coefficients with repeated observations: part 1-correlation within subjects. BMJ 310:446. http://dx.doi.org/10.1136/bmj.310.6977.446.
29. Agresti A, Coull BA. 1996. Order-restricted tests for stratified comparisons of binomial proportions. Biometrics 52:1103-1111. http://dx.doi.org/10.2307/2533072. (Pubitemid 26296088)
30. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz JM. 1999. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 37:937-943. (Pubitemid 29140593)
31. Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, Nuti S, Tavarini S, Sammicheli C, Hilbert AK, Brauer V, Banzhoff A, Rappuoli R, Del Giudice G, Castellino F. 2009. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. U. S. A. 106:3877-3882. http://dx.doi.org/10.1073/pnas. 0813390106.
32. Mir MA, Battiwalla M. 2009. Immune deficits in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Mycopathologia 168:271-282. http://dx.doi.org/10.1007/s11046-009-9181-0.
33. van der Velden MVW, Aichinger G, Pöllabauer EM, Löw-Baselli A, Fritsch S, Benamara K, Kistner O, Müller M, Zeitlinger M, Kollaritsch H, Vesikari T, Ehrlich HJ, Barrett PN. 2012. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming. Vaccine 30:6127-6135. http://dx.doi.org/10.1016/j.vaccine.2012.07.077.
34. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A. 2009. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 4:e4384. http://dx.doi.org/10.1371/journal.pone.0004384.
35. Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney R, Innis B, Fries L. 2010. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J. Infect. Dis. 201:1644-1653. http://dx.doi.org/10.1086/652701.
36. Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, Poling T, Riff D, Baron M, Frenette L, Sheldon E, Collins H, Shepard M, Dionne M, Brune D, Ferguson L, Vaughn D, Li P, Fries L. 2011. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J. Infect. Dis. 203:1729-1738. http://dx.doi.org/10.1093/infdis/jir172.
37. Vesikari T, Forstén A, Herbinger KH, Della Cioppa G, Beygo J, Borkowski A, Groth N, Bennati M, von Sonnenburg F. 2012. Safety and immunogenicity of an MF59-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 30:1388-1396. http://dx.doi.org/10.1016/j. vaccine.2011.12.009.
38. Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HM, Hui DS, Yuen KY, Fritsch S, Aichinger G, Loew-Baselli A, van der Velden M, Maritsch F, Kistner O, Ehrlich HJ. 2012. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine. Vaccine 30:329-335. http://dx.doi.org/10.1016/j.vaccine.2011.10.088.
39. Crowe BA, Brühl P, Gerencer M, Schwendinger MG, Pilz A, Kistner O, Koelling-Schlebusch K, Aichinger G, Singer J, Zeitlinger M, Müller M, Ehrlich H, Barrett PN. 2010. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. Vaccine 29:166-173. http://dx.doi.org/10.1016/j.vaccine.2010. 10.065.
40. Pedersen GK, Madhun AS, Breakwell L, Hoschler K, Sjursen H, Pathirana RD, Goudsmit J, Cox RJ. 2012. T-helper 1 cells elicited by H5N1 vaccination predict seroprotection. J. Infect. Dis. 206:158-166. http://dx.doi.org/10.1093/infdis/ jis330.
41. Maini MK, Gilson RJ, Chavda N, Gill S, Fakoya A, Ross EJ, Phillips AN, Weller IV. 1996. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin. Med. 72:27-31. (Pubitemid 26057871)